SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

SG Americas Securities LLC decreased its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 62.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,581 shares of the company’s stock after selling 36,026 shares during the quarter. SG Americas Securities LLC’s holdings in Neumora Therapeutics were worth $285,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Amalgamated Bank boosted its stake in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares during the period. Quarry LP purchased a new position in Neumora Therapeutics in the second quarter worth approximately $98,000. SkyOak Wealth LLC purchased a new position in Neumora Therapeutics in the second quarter worth approximately $147,000. Principal Financial Group Inc. purchased a new position in Neumora Therapeutics in the second quarter worth approximately $166,000. Finally, Nan Fung Group Holdings Ltd purchased a new position in Neumora Therapeutics in the first quarter worth approximately $871,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NMRA shares. HC Wainwright started coverage on shares of Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a “buy” rating and a $30.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research note on Friday. Finally, Mizuho began coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.83.

Neumora Therapeutics Trading Down 2.8 %

NMRA stock opened at $16.49 on Monday. Neumora Therapeutics, Inc. has a twelve month low of $8.33 and a twelve month high of $21.00. The company’s 50 day moving average is $12.73 and its two-hundred day moving average is $11.33. The stock has a market cap of $2.63 billion and a P/E ratio of -6.44.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). On average, equities research analysts predict that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the sale, the chief financial officer now directly owns 154,658 shares of the company’s stock, valued at approximately $1,821,871.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joshua Pinto sold 31,642 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,538 shares of company stock valued at $1,390,513. Insiders own 26.40% of the company’s stock.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.